SLC2A1

Across TCGA pan-cancer cohorts, SLC2A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC2A1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC2A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC2A1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where SLC2A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.684	0.895	<.001	63	view →
LSCC	OS	Quartile	All	0.941	0.651	.006	32	view →
UCEC	OS	Median	II,III,IV	1.000	0.565	.004	24	view →
LUAD	OS	Median	II,III,IV	0.296	0.857	<.001	23	view →
HNSC	DFS	Tertile	II,III,IV	0.984	0.889	.019	11	view →
CCRCC	OS	Median	II,III,IV	0.633	0.864	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC2A1–PDAC (DFS)

Open the PDAC breakdown →